Drug Development Pharma - August 6, 2014
Boehringer Ingelheim returns project to Orexo
Orexo has announced that Boehringer Ingelheim has decided to return the OX-MPI project to Orexo. The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Since 2005, Boehringer Ingelheim has been responsible for all research and development within the project. Orexo will evaluate the results from Boehringer Ingelheim. When […]
Intellectual Property - June 27, 2014
Orexo commences patent infringement litigation against Actavis
Orexo has filed a patent infringement action in the US District Court for the District of Delaware, against Actavis Elizabeth LLC and its parent company Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application (“ANDA”) filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Orexo’s patented […]
Clinical Trials - June 23, 2014
Orexo reports positive results from phase III trials
The company has announced the results of two phase III clinical trials assessing Zubsolv for induction of buprenorphine maintenance therapy in patients with opioid dependence. Combined data from the Induction, STabilization, Adherence and Retention Trial (ISTART) (Study OX219-006) and Study OX219-007, in 1068 opioid dependent patients, showed that over 90% of patients treated with Zubsolv […]
Business Award - May 21, 2014
SwedenBIO Award to Orexo
Pharmaceutical company Orexo has received this year’s SwedenBIO Award. The award ceremony took place on May 20 during SwedenBIO’s annual meeting. The award was received by Peder Edman, Orexo’s Chief Scientific Officer. The jury’s motivation: “Orexo has during the year succeded in getting Zubsolv both approved and launched in the United States. Swedish life science companies […]
Collaboration - May 20, 2014
New partner for Orexo
Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US. The new partnership agreement replaces existing contracts and will become effective July 1st, 2014 and has a three year term. In the new partnership, Orexo takes the leadership and control of all commercial functions to […]
Agreement - March 12, 2014
Orexo enters agreement for Zubsolv
Orexo AB has announced a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of Zubsolv. Zubsolv is a sublingual tablet formulation for maintenance treatment of opioid dependence. Under the agreement, the product will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for […]
